Early Identification of Pulmonary Coccidioidomycosis


About this study

The purpose of this study is to identify, recruit, and enroll patients with community-acquired pneumonia (CAP) to collect their blood, sputum, urine, and a nasopharyngeal swab for specimen storage. The study also aims to develop a biomarker assay to detect circulating antigen in patients infected with Coccidioides.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

 Inclusion Criteria:                                                                                            

  • Community acquired pneumonia
    • Must have at least two of the following: fever, chills, night sweats, headache, joint aching, muscle pains, cough, rash, fatigue, pain on inspiration, shortness of breath, sputum production
    • CXR or CT evidence of pulmonary infiltrate
    • Inpatient or Outpatient
  • Symptom duration not longer than 14 days
  • Age ≥18 years

 Exclusion Criteria:

  • Known prior coccidioidal illness (prior to onset of current illness).
    • Known prior coccidioidal history
    • Known prior positive coccidioidal skin test
    • Known prior coccidioidal serology in past                         
  • Concurrent nonpulmonary bacterial infection (such as, but not limited to urinary tract infection, sinusitis, C. difficile infection)
  • Health-care associated pneumonia
    • Hospitalization in an acute care hospital for ≥2 days within 90 days of current infection
    • Residence in nursing home or long-term care facility
    • Recent IV antibiotic therapy, chemotherapy or wound care ≤ 30 days prior to current infection
    • Attended a hemodialysis clinic within 30 days
  • Comorbid conditions that increase the PCT levels in the absence of infections including:
    • Medullary thyroid cancer
    • Small cell carcinoma of the lung
    • Carcinoid tumors
    • Pancreatitis
    • Recent trauma, burns or major surgery
  • Receipt of TNF inhibitors, which may theoretically blunt the response of PCT production.
  • No exclusions for underlying health problems other than the above. Patients with underlying immunosuppression will be enrolled only as a subset of total patients enrolled.Acceptable underlying immunosuppression will be defined as the receipt of immunosuppressive medications (within 3 months) such as but not limited to systemic corticosteroids greater than or equal to an equivalent dose of prednisone 5 milligrams daily, calcineurin inhibitors (tacrolimus, etc), mycophenolate mofetil, rapamycin, others.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Janis Blair, M.D.

Open for enrollment

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer